GLUADDA 50mg tablets medication leaflet

A10BH02 vildagliptin • Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Dipeptidyl peptidase 4 (DDP-4) inhibitors

Vildagliptin is a medication used for the treatment of type 2 diabetes. It belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the levels of incretin hormones. These hormones help regulate blood sugar by stimulating insulin secretion and reducing glucagon production, depending on blood glucose levels.

Vildagliptin is taken orally, usually once or twice daily, and can be used alone or in combination with other antidiabetic medications, such as metformin. It is effective in lowering blood sugar levels without typically causing episodes of hypoglycemia.

Side effects may include dizziness, headache, nausea, or, in rare cases, allergic reactions. It is important to use vildagliptin as directed by a healthcare provider, and patients should regularly monitor their blood sugar levels and maintain a healthy lifestyle to maximize the benefits of the treatment.

General data about GLUADDA 50mg

Substance: vildagliptin

Date of last drug list: 01-06-2025

Commercial code: W66805004

Concentration: 50mg

Pharmaceutical form: tablets

Quantity: 30

Product type: generic

Price: 75.20 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: COMBINO PHARM (MALTA) LTD. - MALTA

Holder: MERCK ROMANIA SRL - ROMANIA

Number: 13276/2020/04

Shelf life: 3 years

Concentrations available for vildagliptin

100mg, 50mg

Other substances similar to vildagliptin

Combinations with other substances

Compensation lists for GLUADDA 50mg MERCK SHARP DOHME

NHP 5 (C2) - Diabetes

Price

Copayment

Patient

75.20 RON

44.34 RON

30.86 RON